AstraZeneca PLC Director/PDMR Shareholding (9849Q)

TIDMAZN

RNS Number : 9849Q

AstraZeneca PLC

24 February 2023

24 February 2023 11:00 GMT

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announces that, on 22 February 2023, it was notified by Aradhana Sarin, Executive Director and Chief Financial Officer, that, on 17 February 2023 , Dr Sarin ceased to be beneficially interested in 200 American Depositary Shares (ADSs) of the Company, following the gift of those shares to charity for nil consideration. Each ADS represents one half of an ordinary share of $0.25 each in the Company.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                             Aradhana Sarin 
      -------------------------------  ------------------------------------ 
       Reason for the notification 
  2 
      --------------------------------------------------------------------- 
 a)    Position/status                  Chief Financial Officer 
      -------------------------------  ------------------------------------ 
 b)    Initial notification/Amendment   Initial notification 
      -------------------------------  ------------------------------------ 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------- 
 a)    Name                             AstraZeneca PLC 
      -------------------------------  ------------------------------------ 
 b)    LEI                              PY6ZZQWO2IZFZC3IOL08 
      -------------------------------  ------------------------------------ 
       Details of the transaction(s): section to be repeated 
  4i    for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------- 
 a)    Description of the               AstraZeneca PLC American Depositary 
        financial instrument,            Shares 
        type of instrument 
 
        Identification code              CUSIP: 046353108 
      -------------------------------  ------------------------------------ 
 b)    Nature of the transaction        Gift of shares to charity for nil 
                                         consideration 
      -------------------------------  ------------------------------------ 
 c)    Price(s) and volume(s)             Price(s)   Volume(s) 
                                           0          200 
                                                     ---------- 
      -------------------------------  ------------------------------------ 
 d)    Aggregated information           Not applicable - single transaction 
 
        - Aggregated volume 
        - Price 
      -------------------------------  ------------------------------------ 
 e)    Date of the transaction          17 February 2023 
      -------------------------------  ------------------------------------ 
 f)    Place of the transaction         Outside a trading venue 
      -------------------------------  ------------------------------------

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca .

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUSUWRONUUURR

(END) Dow Jones Newswires

February 24, 2023 06:00 ET (11:00 GMT)

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024